

Sanofi: Chasing the miracles of science to improve people’s lives
Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Supported by Sanofi, Economist Enterprise is focused on quantifying and communicating the profound societal burden of neurological disorders beyond clinical manifestations, exploring economic consequences, caregiver burden and quality of life implications. With approximately one-third of the global population affected by neurological conditions, this partnership aims to translate compelling evidence into actionable policy.
By leveraging Economist Enterprise's analytical expertise and Sanofi's nearly two decades of leadership in neuroscience, we aim to catalyze meaningful dialogue among healthcare stakeholders, policymakers and patient advocates about how biopharmaceutical innovation drives economic growth and creates societal value for global communities. Sanofi strives to decrease the burden of neurological diseases on individuals and society by highlighting innovative approaches to care, identifying unmet needs, and advocating for comprehensive support systems that address both medical and socioeconomic challenges – so we can help people live for the moment and not the disease.

How multilateral organisations can prepare for sustainability
Vaccines are among the most powerful inventions in history, making once-feared diseases preventable

Rethinking how MS disability is measured and managed in the US
75% of neurologists in the US report that a more comprehensive approach is needed to measure disability for people living with MS.